Compare Stocks: XCUR, APLM, ENLV, and LTRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$17.85 +5.6%	$17.61	$3.66 ▼ $42.12	$37.11M	1.46	48,176 shs	4,351 shs
ENLV Enlivex Therapeutics	$2.01 -3.4%	$6.90	$1.80 ▼ $31.50	$35.01M	1.6	381,875 shs	190,262 shs
LTRN Lantern Pharma	$2.81 -1.7%	$3.41	$1.11 ▼ $4.98	$36.49M	2.35	87,814 shs	71,844 shs
XCUR Exicure	$1.37 +1.9%	$2.10	$1.27 ▼ $9.48	$8.57M	3.65	1.19 million shs	59,820 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	0.00%	+3.56%	-7.12%	+23.10%	+209.86%
ENLV Enlivex Therapeutics	0.00%	-0.48%	-69.68%	-81.34%	-90.30%
LTRN Lantern Pharma	0.00%	+8.75%	-20.56%	+36.84%	-42.69%
XCUR Exicure	0.00%	-15.94%	-23.14%	-60.21%	-81.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$17.85 +5.6%	$17.61	$3.66 ▼ $42.12	$37.11M	1.46	48,176 shs	4,351 shs
ENLV Enlivex Therapeutics	$2.01 -3.4%	$6.90	$1.80 ▼ $31.50	$35.01M	1.6	381,875 shs	190,262 shs
LTRN Lantern Pharma	$2.81 -1.7%	$3.41	$1.11 ▼ $4.98	$36.49M	2.35	87,814 shs	71,844 shs
XCUR Exicure	$1.37 +1.9%	$2.10	$1.27 ▼ $9.48	$8.57M	3.65	1.19 million shs	59,820 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	0.00%	+3.56%	-7.12%	+23.10%	+209.86%
ENLV Enlivex Therapeutics	0.00%	-0.48%	-69.68%	-81.34%	-90.30%
LTRN Lantern Pharma	0.00%	+8.75%	-20.56%	+36.84%	-42.69%
XCUR Exicure	0.00%	-15.94%	-23.14%	-60.21%	-81.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	12,213.43% Upside
LTRN Lantern Pharma	1.00	Sell	N/A	N/A
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, APLM, ENLV, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/14/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/23/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/4/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/28/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	4.62	N/A	N/A	($2.89) per share	-6.18
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$0.58 per share	N/A
XCUR Exicure	$500K	17.45	N/A	N/A	$0.62 per share	2.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	8/24/2026 (Estimated)
LTRN Lantern Pharma	-$17.12M	-$1.45	N/A	N/A	N/A	N/A	-198.34%	-129.08%	8/12/2026 (Estimated)
XCUR Exicure	-$4.95M	-$1.55	N/A	N/A	N/A	N/A	-179.41%	-64.37%	8/10/2026 (Estimated)

Latest XCUR, APLM, ENLV, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q1 2026	ENLV Enlivex Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	N/A	N/A	N/A	N/A	N/A
8/10/2026	N/A	XCUR Exicure	-$18.60	N/A	N/A	N/A	$1.64 million	N/A
5/29/2026	Q1 2026	XCUR Exicure	-$18.60	-$0.29	+$18.31	-$0.29	$1.64 million	N/A
5/15/2026	Q1 2026	LTRN Lantern Pharma	-$0.36	-$0.30	+$0.06	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	0.96	0.96
ENLV Enlivex Therapeutics	N/A	193.24	193.24
LTRN Lantern Pharma	N/A	1.87	1.87
XCUR Exicure	N/A	0.79	0.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
ENLV Enlivex Therapeutics	1.02%
LTRN Lantern Pharma	28.62%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
ENLV Enlivex Therapeutics	12.28%
LTRN Lantern Pharma	8.50%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	2.20 million	N/A	Not Optionable
ENLV Enlivex Therapeutics	70	16.83 million	14.77 million	Optionable
LTRN Lantern Pharma	20	12.76 million	11.67 million	Optionable
XCUR Exicure	50	6.37 million	3.01 million	Not Optionable

XCUR, APLM, ENLV, and LTRN Headlines

Recent News About These Companies

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure (XCUR) to Release Quarterly Earnings on Friday

July 31, 2026 | americanbankingnews.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

April 2, 2026 | globenewswire.com

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing

March 25, 2026 | quiverquant.comQ

Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing

March 25, 2026 | quiverquant.comQ

Exicure, Inc. Reports Full Year 2025 Financial Results

March 25, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, APLM, ENLV, and LTRN Company Descriptions

Apollomics NASDAQ:APLM

$17.85 +0.95 (+5.62%)

As of 04:00 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Enlivex Therapeutics NASDAQ:ENLV

$2.01 -0.07 (-3.37%)

As of 04:00 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Lantern Pharma NASDAQ:LTRN

$2.81 -0.05 (-1.75%)

As of 04:00 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Exicure NASDAQ:XCUR

$1.37 +0.03 (+1.86%)

As of 04:00 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, APLM, ENLV, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, APLM, ENLV, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, APLM, ENLV, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, APLM, ENLV, and LTRN Company Descriptions

Apollomics NASDAQ:APLM

Enlivex Therapeutics NASDAQ:ENLV

Lantern Pharma NASDAQ:LTRN

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, APLM, ENLV, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, APLM, ENLV, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, APLM, ENLV, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, APLM, ENLV, and LTRN Company Descriptions

Apollomics NASDAQ:APLM

Enlivex Therapeutics NASDAQ:ENLV

Lantern Pharma NASDAQ:LTRN

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools